CD274 and pancreatic neoplasm: Immune checkpoint inhibitors, represented by PD-1/PD-L1 blockers, are widely believed to be a promising modality in pancreatic cancer, but the high prevalence of immunotherapy resistance of PDAC remains a main obstacle [59].